FDA recently announced that it has implemented new internal procedures for conducting speedy disqualification and debarment proceedings to address congressional and public concern about the potential for a clinical investigator under investigation for disqualification or debarment to compromise drug and device development (or jeopardize patient safety). Among other things, FDA's new time frame procedures are intended to ensure debarment within one year of conviction, similar to FDA's disqualification time frame procedures instituted in June of 2008 that aim for disqualification determinations within one year of clinical investigator inspections noting violations. FDA has assigned an administrative law judge and the Good Clinical Practice Program to oversee disqualification proceedings, and is working to identify staff and a single office to handle debarment proceedings.